Rachel McMinn

Insider Reports History

Entity
Individual
Location
C/O Intercept Pharmaceuticals, Inc., 450 W. 15 Th St., Ste. 505, New York, NY
Signature
/s/ Christine Mikail, as attorney-in-fact for Rachel McMinn
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Rachel McMinn:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Neurogene Inc. Chief Executive Officer, Director Common Stock 1.27M $21.6M $16.94 Mar 26, 2025 Direct
Neurogene Inc. Chief Executive Officer, Director Employee Stock Option (Right to buy) 144K Mar 26, 2025 Direct

Insider Reports Filed by Rachel McMinn

Symbol Company Period Transactions Value $ Form Type Date Filed Role
NGNE Neurogene Inc. Mar 26, 2025 2 $0 4 Mar 28, 2025 Chief Executive Officer, Director
NGNE Neurogene Inc. Nov 22, 2024 1 $969K 4 Nov 25, 2024 Chief Executive Officer, Director
NGNE Neurogene Inc. Mar 13, 2024 1 $0 4 Mar 14, 2024 Chief Executive Officer, Director
NGNE Neurogene Inc. Dec 18, 2023 0 $0 3 Dec 26, 2023 Chief Executive Officer, Director